Strensiq and Injection site atrophy - a phase IV clinical study of FDA data

Summary:

Injection site atrophy is found among people who take Strensiq, especially for people who are female, 2-9 old, have been taking the drug for 2 - 5 years.

The phase IV clinical study analyzes which people take Strensiq and have Injection site atrophy. It is created by eHealthMe based on reports of 5,789 people who have side effects when taking Strensiq from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Sep, 18, 2023

5,789 people reported to have side effects when taking Strensiq.
Among them, 73 people (1.26%) have Injection site atrophy.

What is Strensiq?

Strensiq has active ingredients of asfotase alfa. eHealthMe is studying from 5,791 Strensiq users for its effectiveness, alternative drugs and more.

What is Injection site atrophy?

Injection site atrophy (injection site wasting or decreasing in size of a body organ, tissue, or part) is found to be associated with 384 drugs and 195 conditions by eHealthMe.

Number of Strensiq and Injection site atrophy reports submitted per year:

Could Strensiq cause Injection site atrophy?

Time on Strensiq when people have Injection site atrophy *:

Gender of people who have Injection site atrophy when taking Strensiq *:

female: 54.55 %
male: 45.45 %

Age of people who have Injection site atrophy when taking Strensiq *:

Common drugs people take besides Strensiq *:

Common side effects people have besides Injection site atrophy *:

Injection Site Pain: 23 people, 31.51%
Injection Site Reaction: 20 people, 27.40%
Injection Site Erythema (redness at injection site): 19 people, 26.03%
Injection Site Swelling: 12 people, 16.44%
Injection Site Bruising: 12 people, 16.44%
Drug Ineffective: 9 people, 12.33%
Blood Alkaline Phosphatase Increased: 6 people, 8.22%
Joint Pain: 5 people, 6.85%
Bone Pain: 5 people, 6.85%
Weight Increased: 5 people, 6.85%

Common conditions people have *:

Hypophosphatasia (metabolic bone disease): 47 people, 64.38%
Inflammatory Bowel Disease: 2 people, 2.74%
Seasonal Allergy (allergic condition due to certain season): 1 person, 1.37%
Nasopharyngitis (inflammation of the nasopharynx): 1 person, 1.37%
Cough: 1 person, 1.37%

* Approximation only. Some reports may have incomplete information.

Do you take Strensiq and have Injection site atrophy?

Check whether Injection site atrophy is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Injection site atrophy and when was it recovered:

Injection site atrophy in Strensiq

Expand to all the drugs that have ingredients of asfotase alfa:

Injection site atrophy and drugs with ingredients of asfotase alfa

Alternative drugs to, pros and cons of Strensiq:

Strensiq (5,791 reports)

Common Strensiq side effects:

Fatigue (feeling of tiredness): 422 reports
Pain: 413 reports
Joint pain: 272 reports

Browse all side effects of Strensiq:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Injection site atrophy treatments and more:

Injection site atrophy (1,600 reports)

COVID vaccines that are related to Injection site atrophy:

Common drugs associated with Injection site atrophy:

Kenalog: 345 reports
Copaxone: 313 reports
Avonex: 179 reports
Kenalog-40: 156 reports

How the study uses the data?

The study uses data from the FDA. It is based on asfotase alfa (the active ingredients of Strensiq) and Strensiq (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.